Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

about

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Item

http://www.wikidata.org/entity/Q38909078

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

@en

type

Item

label

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

@en

prefLabel

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

@en

P1476

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors

@en

P2093

Natalie Prinzi

http://www.w3.org/2001/XMLSchema#string

Roberto Buzzoni

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

P2888

s13277-016-5258-9

P304

12991-13003

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-016-5258-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039866590

http://www.w3.org/2001/XMLSchema#string

P698

27460087

http://www.w3.org/2001/XMLSchema#string